[go: up one dir, main page]

DE10164510A1 - Oral Fludara pure formulation with rapid release of the active ingredient - Google Patents

Oral Fludara pure formulation with rapid release of the active ingredient

Info

Publication number
DE10164510A1
DE10164510A1 DE10164510A DE10164510A DE10164510A1 DE 10164510 A1 DE10164510 A1 DE 10164510A1 DE 10164510 A DE10164510 A DE 10164510A DE 10164510 A DE10164510 A DE 10164510A DE 10164510 A1 DE10164510 A1 DE 10164510A1
Authority
DE
Germany
Prior art keywords
fludara
purin
amine
tablet formulation
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE10164510A
Other languages
German (de)
Inventor
Wolfgang Heil
Ralph Lipp
Johannes Wilhelm Tack
Ulf Tilstam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7711168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10164510(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering AG filed Critical Schering AG
Priority to DE10164510A priority Critical patent/DE10164510A1/en
Priority to AT02781328T priority patent/ATE303797T1/en
Priority to IL16255502A priority patent/IL162555A0/en
Priority to CNB028279034A priority patent/CN1306929C/en
Priority to RU2004122479/15A priority patent/RU2318496C2/en
Priority to AU2002349043A priority patent/AU2002349043B2/en
Priority to PCT/EP2002/013252 priority patent/WO2003053418A1/en
Priority to MXPA04006005A priority patent/MXPA04006005A/en
Priority to EP02781328A priority patent/EP1455760B1/en
Priority to UA20040705884A priority patent/UA78741C2/en
Priority to YUP-533/04A priority patent/RS50398B/en
Priority to DE50204203T priority patent/DE50204203D1/en
Priority to PL370792A priority patent/PL203451B1/en
Priority to ES02781328T priority patent/ES2248624T3/en
Priority to BR0215265-7A priority patent/BR0215265A/en
Priority to DK02781328T priority patent/DK1455760T3/en
Priority to CA002471396A priority patent/CA2471396A1/en
Priority to JP2003554177A priority patent/JP2005519043A/en
Priority to KR1020047009750A priority patent/KR100884685B1/en
Priority to NZ533701A priority patent/NZ533701A/en
Priority to JO2002123A priority patent/JO2363B1/en
Priority to UY27596A priority patent/UY27596A1/en
Priority to ARP020105054A priority patent/AR037965A1/en
Priority to US10/324,141 priority patent/US7148207B2/en
Priority to TW091136814A priority patent/TWI255187B/en
Priority to PE2003000017A priority patent/PE20030639A1/en
Priority to SA03240091A priority patent/SA03240091B1/en
Publication of DE10164510A1 publication Critical patent/DE10164510A1/en
Priority to IL162555A priority patent/IL162555A/en
Priority to EC2004005185A priority patent/ECSP045185A/en
Priority to HR20040648 priority patent/HRP20040648B1/en
Priority to NO20043063A priority patent/NO20043063L/en
Priority to ZA2004/05735A priority patent/ZA200405735B/en
Priority to HK05109796A priority patent/HK1077741A1/en
Priority to JP2005379628A priority patent/JP2006137771A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention relates to a fast releasing tablet formulation containing <99.19 % of pure Fludara (ultrapure Fludara) as an active substance in a defined composition of remaining impurities.

Description

Die vorliegende Erfindung betrifft eine schnellfreisetzende Tabletten-Formulierung mit > 99,19% reinem Fludara (reinst Fludara)


als Wirkstoff in definierter Zusammensetzung der Restverunreinigungen. The present invention relates to a rapid-release tablet formulation with> 99.19% pure Fludara (purest Fludara)


as active ingredient in a defined composition of the residual impurities.

Tabletten-Formulierungen mit Fludara in einer Reinheit von < 98% sind bereits bekannt In den nachfolgenden Arbeiten werden u. a. verschiedene Formulierungen und Dosierungen aufgeführt (7 Modern Pharmaceutics, Chapters 9 and 10, Banker & Rhodes, Editors, 1979; Liebennan et al., Pharmaceitical Dosage Forms: Tablets, 1981; Ansel, Introduction to Pharmaceutical Dosage Forms 2nd Edition, 1976). Tablet formulations with Fludara in a purity of <98% are already known In the following works u. a. different formulations and Dosages listed (7 Modern Pharmaceutics, Chapters 9 and 10, Banker & Rhodes, Editors, 1979; Liebennan et al., Pharmaceutical Dosage Forms: Tablets, 1981; Ansel, Introduction to Pharmaceutical Dosage Forms 2nd Edition, 1976).

In der US 3,903,297 wird exemplarisch eine Tabletten-Formulierungen aus Wirkstoff mit Lactose, mikrokristalliner Cellulose, kolloidalem Siliciumdioxid und Magnesiumstearat beschrieben (Beispiel 2). Daß eine Formulierung auch Croscaramellose-Na enthalten kann, ist ebenfalls exemplarisch beschrieben (Beispiel 5). In der WO 00/71134 werden allgemein Tabletten-Formulierungen aus Lactose, mikrokristalliner Cellulose, kolloidalem Siliciumdioxid, Croscaramellose-Na und Magnesiumstearat beschrieben. Ferner kann eine solche Zusammensetzung eine chemotherapeutische Substanz enthalten. US Pat. No. 3,903,297 exemplifies a tablet formulation of active ingredient Lactose, microcrystalline cellulose, colloidal silica and magnesium stearate described (Example 2). That a formulation also contains croscaramellose-na can, is also described by way of example (Example 5). In WO 00/71134 are general tablet formulations of lactose, microcrystalline cellulose, colloidal silica, croscaramellose Na and magnesium stearate. Furthermore, such a composition may be a chemotherapeutic substance contain.

Aus der WO 97/40846 sind Tablettenüberzüge bekannt, die Hydroxypropylmethylcellulose, Titandioxid und Pigmente, wie z. B. Eisenoxidpigmente enthalten. From WO 97/40846 tablet coatings are known which Hydroxypropylmethylcellulose, titanium dioxide and pigments, such as. B. iron oxide pigments.

Aus der WO 00/50423 sind Tabletten-Formulierungen aus Lactose, mikrokristalliner Cellulose, Croscaramellose-Na, etc. bekannt, die sich schnell lösen. From WO 00/50423 are tablet formulations of lactose, microcrystalline Cellulose, Croscaramellose-Na, etc., which dissolve quickly.

In der 6,197,785, EP 1065206, EP 819430, EP 1065204 und EP 985666 werden verwendbare Tabletten- Formulierungen für die orale Applikation beschrieben, die aus Lactose, mikrokristalliner Cellulose, kolloidalem Siliciumdioxid, Magnesiumstearat, Croscaramellose-Na, Talcum, etc. bestehen. Als Wirkstoff kann u. a. Fludara enthalten sein. In 6,197,785, EP 1065206, EP 819430, EP 1065204 and EP 985666 are usable tablet formulations for oral administration described in Lactose, microcrystalline cellulose, colloidal silica, magnesium stearate, Croscaramellose-Na, Talcum, etc. exist. As an active ingredient u. a. Fludara included his.

Fludara-Formulierungen, die den Wirkstoff in einer Reinheit von > 99,5% auweisen und eine Definierte Zusammensetzung der Verunreinigungen des Wirkstofes in der Formulierung offenbaren, sind bisher nicht bekannt. Fludara formulations which have the active ingredient in a purity of> 99.5% and a defined composition of the impurities of the active substance in the Formulation reveal, are not yet known.

Aus der WO 99/29710 ist der Wirkstoff Fludara mit einer Reinheit von > 99,19% bekannt. Aber auch in diesem Stand der Technik wird keine definierte Zusammensetzung des reinen, in einer Formulierung enthaltenen Fludara gegeben. From WO 99/29710 the active substance Fludara with a purity of> 99.19% known. But even in this state of the art is no defined Composition of the pure, contained in a formulation Fludara given.

Es wäre deshalb auch wünschenswert, eine stabile Tabletten-Formulierung zu haben, die Fludara in hoher Reinheit mit definierter Konzentration an Rest-Verunreinigungen aufweist, die schnellauflösend ist und damit den Wirkstoff schnell abgibt. It would therefore also be desirable to have a stable tablet formulation the fludara in high purity with a defined concentration of residual impurities has, which is fast dissolving and thus gives off the drug quickly.

Es wurde nun gefunden, daß mit einer Tabletten-Formulierung, in der der Wirkstoff Fludara in einer Reinheit von > 99,19% in nicht-mikronisierter, aber gesiebter Form, mit definierter Konzentration an Rest-Verunreinigung vorliegt, die Nachteile der bekannten Tabletten überwindet. It has now been found that with a tablet formulation in which the active ingredient Fludara in> 99.19% purity in non-micronised but sieved form, with defined concentration of residual contamination, the disadvantages of the known Tablets overcomes.

Die Tablettenformulierung umfaßt den Wirkstoff in einer Menge von 5 bis 100 mg, vorzugsweise von 8 bis 75 mg, besonders bevorzugt in einer Menge von 10 bis 50 mg, ausgewählt in einer Menge von 10 bis 20 mg. The tablet formulation comprises the active ingredient in an amount of 5 to 100 mg, preferably from 8 to 75 mg, more preferably in an amount of from 10 to 50 mg, selected in an amount of 10 to 20 mg.

Die bevorzugten Formulierungsstoffe sind Lactose, kolloidales Siliciumdioxid mikrokristalline Cellulose (Avicel), Crosscaramellose-Natrium (Natriumcarboxymethylcellulose) und Magnesium-Stearat. The preferred formulants are lactose, colloidal silica microcrystalline cellulose (avicel), crosscaramellose sodium (Sodium carboxymethylcellulose) and magnesium stearate.

Es sind aber auch andere, dem Fachmann allgemein bekannte Formulierungsstoffe denkbar. But there are also other formulators generally known to those skilled in the art conceivable.

Die Formulierungsstoffe in der Tablette umfassen eine Gesamt-Menge von 100 bis 250 mg, vorzugsweise eine Gesamt-Menge von 120 bis 200 mg, besonders bevorzugt eine Gesamt-Menge von 130 bis 180 mg. The formulants in the tablet comprise a total amount of 100 to 250 mg, preferably a total amount of from 120 to 200 mg, more preferably one Total amount from 130 to 180 mg.

Gegenstand der vorliegenden Erfindung ist somit eine schnellfreisetzende Tabletten- Formulierung, umfassend 1 bis 100 mg des Wirkstoffes Fludara in einer Reinheit von > 99,19%, zusammen mit
Lactose Monohydrat,
kolloidalem Siliciumdioxid,
mikrokristalliner Cellulose (Avicel),
Croscaramellose-Na (Natriumcarboxymethylcellulose),
und Magnesiumstearat,
dadurch gekennzeichnet, daß die Verunreinigungen im Fludara einen Prozentsatz wie folgt nicht überschreiten:
0,02% 2-Fluor-9-(β-D-arabino-furanosyl)-9H-purin-6-amin,
0,12% 6-Amino-9(5-O-phosphono-β-D-arabino-furanosyl)-9H-purin-2-ol,
0,02% 2-Fluor-9H-purin-6-amin,
0,02% 6-Amino-9H-purin-2-ol,
0,05% 2-Fluor-9-(5-O-phosphono-β-D-ribofuranosyl)-9H-purin-6-amin,
0,1% 9-(3,5-O-diphosphono-β-D-arabi-nofuranosyl)-2-fluoro-9H-purin-6-amin,
0,1% 9-(2,5-O-diphosphono-β-D-ara-binofuranosyl)-2-fluoro-9H-purin-6-amin,
0,02% 2-Fluor-9-(5-O-phosphono-β-D-arabinofuranosyl)-9H-purin-6-amin,
0,06% 2-Ethoxy-9-(5-O-phosphono-β-D-arabinofuranosyl)-9H-purin-6-amin,
0,02% 2-(6-Amino-9H-purin-2-yl)-9-(5-O-phosphono-β-D-ara-binofuranosyl)- 9H-purin-6-amin und O,O'-Bis[2-(6-amino-2-fluor-9H-purin-9-yl)-5-deoxy- α-D-arabinofuranos-5-yl]-phosphat,
0,1% 9-(2-Chlor-2-deoxy-5-phosphono-β-D-ara-binofuranosyl)-2-fluor-9H- purin-6-amin und
0,1% 9-(2,5-Anhydro-β-D-arabino-furanosyl)-2-fluor-9H-purin-6-amin. The present invention thus relates to a rapid-release tablet formulation comprising 1 to 100 mg of the active ingredient Fludara in a purity of> 99.19%, together with
Lactose monohydrate,
colloidal silica,
microcrystalline cellulose (Avicel),
Croscaramellose Na (sodium carboxymethylcellulose),
and magnesium stearate,
characterized in that the impurities in the fludara do not exceed a percentage as follows:
0.02% 2-fluoro-9- (β-D-arabino-furanosyl) -9H-purin-6-amine,
0.12% 6-amino-9 (5-O-phosphono-β-D-arabino-furanosyl) -9H-purin-2-ol,
0.02% 2-fluoro-9H-purin-6-amine,
0.02% 6-amino-9H-purin-2-ol,
0.05% 2-fluoro-9- (5-O-phosphono-β-D-ribofuranosyl) -9H-purin-6-amine,
0.1% 9- (3,5-O-diphosphono-β-D-arabinofuranosyl) -2-fluoro-9H-purin-6-amine,
0.1% 9- (2,5-O-diphosphono-β-D-ara-binofuranosyl) -2-fluoro-9H-purin-6-amine,
0.02% 2-fluoro-9- (5-O-phosphono-β-D-arabinofuranosyl) -9H-purin-6-amine,
0.06% 2-ethoxy-9- (5-O-phosphono-β-D-arabinofuranosyl) -9H-purin-6-amine,
0.02% 2- (6-amino-9H-purin-2-yl) -9- (5-O-phosphono-β-D-ara-binofuranosyl) -9H-purin-6-amine and O, O ' Bis [2- (6-amino-2-fluoro-9H-purin-9-yl) -5-deoxy-α-D-arabinofuranos-5-yl] -phosphate,
0.1% 9- (2-chloro-2-deoxy-5-phosphono-β-D-ara-binofuranosyl) -2-fluoro-9H-purin-6-amine and
0.1% 9- (2,5-anhydro-β-D-arabino-furanosyl) -2-fluoro-9H-purin-6-amine.

Bevorzugt ist eine schnellfreisetzende Tabletten-Formulierung, die
1 bis 70,00 mg des Wirkstoffes Fludara in einer Reinheit von > 99,19%, zusammen mit
50 bis 100 mg Lactose Monohydrat,
0,1 bis 5 mg kolloidales Siliciumdioxid,
40 bis 100 mg mikrokristalline Cellulose (Avicel),
1 bis 10 mg Croscaramellose-Na (Natriumcarboxymethylcellulose) und
0,5 bis 10 mg Magnesiumstearat umfaßt. Preferred is a fast-release tablet formulation, the
1 to 70.00 mg of the active substance Fludara in a purity of> 99.19%, together with
50 to 100 mg lactose monohydrate,
0.1 to 5 mg of colloidal silica,
40 to 100 mg of microcrystalline cellulose (Avicel),
1 to 10 mg croscaramellose-Na (sodium carboxymethylcellulose) and
0.5 to 10 mg of magnesium stearate.

Besonders bevorzugt sind solche schnellfreisetzenden Tabletten-Formulierungen, die 1 bis 50,00 mg des Wirkstoffes Fludara in einer Reinheit von > 99,19%, zusammen mit 60 bis 90 mg Lactose Monohydrat,
0,5 bis 1 mg kolloidales Siliciumdioxid,
50 bis 90 mg mikrokristalline Cellulose (Avicel),
1,5 bis 5 mg Croscaramellose-Na (Natriumcarboxymethylcellulose) und
1 bis 3 mg Magnesiumstearat umfassen. Particularly preferred are those fast-release tablet formulations containing 1 to 50.00 mg of the active ingredient Fludara in a purity of> 99.19%, together with 60 to 90 mg of lactose monohydrate,
0.5 to 1 mg of colloidal silica,
50 to 90 mg of microcrystalline cellulose (Avicel),
1.5 to 5 mg croscaramellose Na (sodium carboxymethylcellulose) and
1 to 3 mg of magnesium stearate.

Ausgewählt ist eine solche schnellfreisetzenden Tabletten-Formulierungen, die 10 mg des Wirkstoffes Fludara in einer Reinheit von > 99,19%, zusammen mit
74,75 mg Lactose Monohydrat,
0,75 mg kolloidales Siliciumdioxid,
60,00 mg mikrokristalline Cellulose (Avicel),
3,00 mg Croscaramellose-Na (Natriumcarboxymethylcellulose) und
1,5-2,00 mg Magnesiumstearat umfassen. Selected is such a rapid-release tablet formulations containing 10 mg of the active ingredient Fludara in a purity of> 99.19%, together with
74.75 mg lactose monohydrate,
0.75 mg of colloidal silica,
60.00 mg of microcrystalline cellulose (Avicel),
3.00 mg croscaramellose Na (sodium carboxymethylcellulose) and
1.5-2.00 mg magnesium stearate.

Bevorzugt sind auch solche Formulierungen, die den Wirkstoff Fludara in einer Reinheit von > 99,37% umfassen. Also preferred are those formulations which contain the active ingredient Fludara in a purity of> 99.37%.

Noch bevorzugter sind solche Formulierungen, die den Wirkstoff Fludara in einer Reinheit von > 99,57% umfassen. Even more preferred are those formulations containing the active ingredient Fludara in one Purity of> 99.57%.

Besonders bevorzugt sind solche Formulierungen, die den Wirkstoff Fludara in einer Reinheit von > 99,80% umfassen. Particularly preferred are those formulations containing the active ingredient Fludara in a Purity of> 99.80%.

Insbesondere bevorzugt sind solche Formulierungen, die den Wirkstoff Fludara in einer Reinheit von > 99,85% umfassen. Particularly preferred are those formulations which contain the active ingredient Fludara in one Purity of> 99.85%.

Die erfindungsgemäßen Formulierungen werden gemäß allgemein bekannter Methoden zu Preßmassen verarbeitet, die anschließend zu Tablettenkernen verpreßt werden. Diese Tablettenkerne können mit allgemein bekannten Methoden mit Überzügen versehen werden. Es können im Prinzip alle dem Fachmann bekannten Überzüge verwendet werden. Ein bevorzugter Überzug umfaßt z. B. die folgenden Bestandteile
1 bis 5 mg, vorzugsweise 1 bis 3 mg, besonders bevorzugt 2,250 mg Hydroxypropylmethylcellulose,
0,1 bis 1 mg, vorzugsweise 0,1 bis 0,8 mg, besonders bevorzugt 0,450 mg Talkum,
0,1 bis 5 mg, vorzugsweise 0,1 bis 2 mg, besonders bevorzugt 1,187 mg Titandioxid,
0,01 bis 0,1 mg, vorzugsweise 0,01 bis 0,05 mg, besonders bevorzugt 0,036 mg gelbes Eisenoxidpigment und
0,01 bis 0,1 mg, vorzugsweise 0,01 bis 0,05 mg, besonders bevorzugt 0,036 mg rotes Eisenoxidpigment. The formulations of the invention are processed according to well-known methods to molding compositions, which are then pressed into tablet cores. These tablet cores can be provided with coatings by well-known methods. In principle, all coatings known to the person skilled in the art can be used. A preferred coating comprises, for. For example, the following ingredients
1 to 5 mg, preferably 1 to 3 mg, more preferably 2,250 mg of hydroxypropylmethylcellulose,
0.1 to 1 mg, preferably 0.1 to 0.8 mg, more preferably 0.450 mg talc,
0.1 to 5 mg, preferably 0.1 to 2 mg, more preferably 1.187 mg of titanium dioxide,
0.01 to 0.1 mg, preferably 0.01 to 0.05 mg, particularly preferably 0.036 mg of yellow iron oxide pigment and
0.01 to 0.1 mg, preferably 0.01 to 0.05 mg, particularly preferably 0.036 mg of red iron oxide pigment.

Diese Überzüge sind ebenfalls Gegenstand der vorliegenden Erfindung. These coatings are also the subject of the present invention.

Die efindungsgemäßen Tabletten-Formulierung können zur Herstellung eines Medikaments zur Behandlung von Krebs verwendet werden. The tablet formulation according to the invention can be used to prepare a Drug used to treat cancer.

Die vorliegende Erfindung umfaßt somit auch die Verwendung der erfindungsgemäßen Formulierungen zur Herstellung eines Medikaments zur Behandlung von Krebs. The present invention thus also encompasses the use of the invention Formulations for the manufacture of a medicament for the treatment of cancer.

Die nachfolgenden Beispiele beschreiben die Herstellung der erfindungsgemäßen Fludara reinst Tabletten-Formulierungen sowie einen Vergleich der herkömmlichen Zusammensetzung des < 98%-igen reinen Fludara mit dem > 99,19% reinem Fludara. The following examples describe the preparation of the invention Fludara reinstates tablet formulations as well as a comparison of conventional ones Composition of <98% pure fludara with> 99.19% pure fludara.

Beispiel 1example 1 Herstellung einer Tabletten-FormulierungPreparation of a tablet formulation

Für die Herstellung einer erfindungsgemäßen Tabletten-Formulierung wird der Wirkstoff Fludara (Fludarabinphosphat) zunächst gesiebt und anschließend mit Lactose Monohydrat, mikrokristalliner Cellulose (Avicel) und kolloidalem Siliciumdioxid zu einer etwa 30%-igen Trockenmischung verarbeitet. Das Gemisch wird anschließend ebenfalls gesiebt. Die Qualität bzw. Partikelgröße wird mittels Siebanalyse geprüft. Anschließend werden Crosscaramellose Natrium (Natriumcarboxymethylcellulose) und Magnesiumstearat in weiteren Mischsequenzen sukzessive zur Trockenmischung zugegeben. For the preparation of a tablet formulation according to the invention, the active ingredient Fludara (fludarabine phosphate) first sieved and then with lactose Monohydrate, microcrystalline cellulose (Avicel) and colloidal silica to a processed about 30% dry mix. The mixture is subsequently also sieved. The quality or particle size is checked by sieve analysis. Subsequently, Crosscaramellose sodium (sodium carboxymethylcellulose) and Magnesium stearate in further mixing sequences successively for dry mixing added.

Die Preßmasse wird zu Tablettenkernen verpreßt. The molding compound is pressed into tablet cores.

Eine so hergestellte Tabletten-Formulierung umfaßt zum Beispiel die folgenden Einzelbestandteile
Fludara > 99,19% reinst 10,00 mg Lactose Monohydrat 74,75 mg kolloidales Siliciumdioxid 0,75 mg mikrokristalline Cellulose (Avicel) 60,00 mg Croscaramellose-Na (Natriumcarboxymethylcellulose) 3,00 mg Magnesiumstearat 1,5-2,00 mg A tablet formulation thus prepared comprises, for example, the following individual ingredients
Fludara> 99.19% pure 10.00 mg Lactose monohydrate 74.75 mg colloidal silica 0.75 mg microcrystalline cellulose (Avicel) 60.00 mg Croscaramellose Na (sodium carboxymethylcellulose) 3.00 mg magnesium stearate 1.5-2.00 mg

Anschließend werden die Tablettenkerne mit einer wässrigen Filmsuspension lackiert. Ein solcher Filmüberzug umfaßt zum Beispiel die folgenden Bestandteile: Hydroxypropylmethylcellulose 2,250 mg Talkum 0,450 mg Titandioxid 1,187 mg Eisenoxidpigment, gelb 0,036 mg Eisenoxidpigment, rot 0,036 mg Subsequently, the tablet cores are painted with an aqueous film suspension. Such a film coating comprises, for example, the following components: hydroxypropyl methylcellulose 2,250 mg talc 0.450 mg Titanium dioxide 1.187 mg Iron oxide pigment, yellow 0.036 mg Iron oxide pigment, red 0.036 mg

Das Gesamtgewicht der Tablette beträgt 154 mg. The total weight of the tablet is 154 mg.

Die so hergestellten Filmtabletten können anschließend weiter verarbeitet werden. So können die Filmtabletten z. B. in Alu-Blister verpackt werden, wodurch die Stabilität der Formulierung gewährleistet wird. The film-coated tablets produced in this way can then be further processed. So can the film-coated tablets z. B. be packaged in aluminum blister, causing the stability of Formulation is guaranteed.

Beispiel 2Example 2

Vergleich einer herkömmlichen Zusammensetzung des < 98%-igen (97,67%) reinen Fludara mit dem > 99,19%, bzw. > 99,57% reinen Fludara und dem über einen Ionenaustauscher gereinigtem 99,19%-igen Fludara. Comparison of a conventional composition of <98% (97.67%) pure Fludara with> 99.19%, resp.> 99.57% pure Fludara and over one Ion exchanger purified 99.19% fludara.

Die Ergebnisse sind in der nachfolgenden Tabelle aufgeführt.











The results are listed in the table below.











Die Ergebnisse zeigen, daß eine Formulierung aus käuflichem Fludara (maximal 97,67%-iges Fludara) oder eine Formulierung mit über einen Ionenaustauscher gereinigtem Fludara (maximal 99,19%-iges Fludara) deutlich mehr verunreinigende Nebenprodukte aufweisen, als das in den erfindungsgemäßen Formulierungen enthaltene reinst Fludara (> 99,37%-iges bis > 99,57%-iges Fludara). The results show that a formulation of commercial Fludara (maximum 97.67% Fludara) or a formulation with Fludara purified via an ion exchanger (maximum 99.19% Fludara) have significantly more contaminating byproducts than contained in the formulations of the invention purest Fludara (> 99.37% to > 99.57% Fludara).

Mit herkömmlichen Reinigungsverfahren, wie der sehr potenten Ionenaustauschchromatographie läßt sich nur ein recht mäßiger Reinheitsgrad erzielen. With conventional cleaning methods, such as the very potent Ion exchange chromatography can only achieve a fairly moderate degree of purity.

Die erfindungsgemäßen Fludara-Formulierungen enthalten das über das Natriumsalz freigesetzte reinst Fludara, was bereits in der WO 99/29710 beschrieben wird. Ein noch höherer Reinheitsgrad des Fludara kann über das Kaliumsalz (99,8%) oder über das Lithiumsalz (99,85%) hergestellt werden. The fludara formulations according to the invention contain that via the sodium salt liberated purest fludara, which is already described in WO 99/29710. One more higher degree of purity of the Fludara can over the potassium salt (99.8%) or over the Lithium salt (99.85%) are produced.

Claims (12)

1. Schnellfreisetzende Tabletten-Formulierung, umfassend 1 bis 100 mg des Wirkstoffes Fludara in einer Reinheit von > 99,19%, zusammen mit
Lactose Monohydrat,
kolloidalem Siliciumdioxid,
mikrokristalliner Cellulose (Avicel),
Croscaramellose-Na (Natriumcarboxymethylcellulose),
und Magnesiumstearat,
dadurch gekennzeichnet, daß die Verunreinigungen im Fludara einen Prozentsatz wie folgt nicht überschreiten:
0,02% 2-Fluor-9-(β-D-arabino-furanosyl)-9H-purin-6-amin
0,12% 6-Amino-9(5-O-phosphono-β-D- arabino-furanosyl)-9H-purin-2-ol
0,02% 2-Fluor-9H-purin-6-amin
0,02% 6-Amino-9H-purin-2-ol
0,05% 2-Fluor-9-(5-O-phosphono-β-D-ribofuranosyl)-9H-purin-6-amin
0,1% 9-(3,5-O-diphosphono-β-D-arabi-nofuranosyl)-2-fluoro-9H-purin-6- amin
0,1% 9-(2,5-O-diphosphono-β-D-ara-binofuranosyl)-2-fluoro-9H-purin-6- amin
0,02% 2-Fluor-9-(5-O-phosphono-β-D-arabinofuranosyl)-9H-purin-6- amin
0,06% 2-Ethoxy-9-(5-O-phosphono-β-D-arabinofuranosyl)-9H-purin-6- amin
0,02% 2-(6-Amino-9H-purin-2-yl)-9-(5-O-phosphono-β-D-arabinofuranosyl)-9H-purin-6-amin und O,O'-Bis[2-(6-amino-2-fluor- 9H-purin-9-yl)-5-deoxya-D-arabinofuranos-5-yl]-phosphat,
0,1% 9-(2-Chlor-2-deoxy-5-phosphono-β-D-ara-binofuranosyl)-2-fluor- 9H-purin-6-amin
0,1% 9-(2,5-Anhydro-β-D-arabino-furanosyl)-2-fluoro-9H-purin-6-amine. A rapid-release tablet formulation comprising 1 to 100 mg of the active ingredient Fludara in a purity of> 99.19%, together with
Lactose monohydrate,
colloidal silica,
microcrystalline cellulose (Avicel),
Croscaramellose Na (sodium carboxymethylcellulose),
and magnesium stearate,
characterized in that the impurities in the fludara do not exceed a percentage as follows:
0.02% 2-fluoro-9- (β-D-arabino-furanosyl) -9H-purin-6-amine
0.12% 6-amino-9 (5-O-phosphono-β-D-arabino-furanosyl) -9H-purin-2-ol
0.02% 2-fluoro-9H-purin-6-amine
0.02% 6-amino-9H-purin-2-ol
0.05% 2-fluoro-9- (5-O-phosphono-β-D-ribofuranosyl) -9H-purin-6-amine
0.1% 9- (3,5-O-diphosphono-β-D-arabinofuranosyl) -2-fluoro-9H-purine-6-amine
0.1% 9- (2,5-O-diphosphono-β-D-ara-binofuranosyl) -2-fluoro-9H-purine-6-amine
0.02% 2-fluoro-9- (5-O-phosphono-β-D-arabinofuranosyl) -9H-purine-6-amine
0.06% 2-ethoxy-9- (5-O-phosphono-β-D-arabinofuranosyl) -9H-purine-6-amine
0.02% 2- (6-amino-9H-purin-2-yl) -9- (5-O-phosphono-β-D-arabinofuranosyl) -9H-purin-6-amine and O, O'-bis [2- (6-amino-2-fluoro-9H-purin-9-yl) -5-deoxy-D-arabinofuranos-5-yl] -phosphate,
0.1% 9- (2-chloro-2-deoxy-5-phosphono-β-D-ara-binofuranosyl) -2-fluoro-9H-purin-6-amine
0.1% 9- (2,5-anhydro-β-D-arabino-furanosyl) -2-fluoro-9H-purin-6-amine. 2. Schnellfreisetzende Tabletten-Formulierung gemäß Anspruch 1, die
1 bis 70 mg des Wirkstoffes Fludara in einer Reinheit von > 99,19%, zusammen mit 50 bis 100 mg Lactose Monohydrat,
0,1 bis 5 mg kolloidales Siliciumdioxid,
40 bis 100 mg mikrokristalline Cellulose (Avicel),
1 bis 10 mg Croscaramellose-Na (Natriumcarboxymethylcellulose) und
0,5 bis 10 mg Magnesiumstearat umfaßt. 2. Fast-release tablet formulation according to claim 1, which
1 to 70 mg of the active substance Fludara in a purity of> 99.19%, together with 50 to 100 mg of lactose monohydrate,
0.1 to 5 mg of colloidal silica,
40 to 100 mg of microcrystalline cellulose (Avicel),
1 to 10 mg croscaramellose-Na (sodium carboxymethylcellulose) and
0.5 to 10 mg of magnesium stearate. 3. Schnellfreisetzende Tabletten-Formulierung gemäß den Ansprüchen 1 und 2, die
1 bis 50 mg des Wirkstoffes Fludara in einer Reinheit von > 99,19%, zusammen mit 60 bis 90 mg Lactose Monohydrat,
0,5 bis 1 mg kolloidales Siliciumdioxid,
50 bis 90 mg mikrokristalline Cellulose (Avicel),
1,5 bis 5 mg Croscaramellose-Na (Natriumcarboxymethylcellulose) und
1 bis 3 mg Magnesiumstearat umfaßt. 3. Fast-release tablet formulation according to claims 1 and 2, which
1 to 50 mg of the active substance Fludara in a purity of> 99.19%, together with 60 to 90 mg of lactose monohydrate,
0.5 to 1 mg of colloidal silica,
50 to 90 mg of microcrystalline cellulose (Avicel),
1.5 to 5 mg croscaramellose Na (sodium carboxymethylcellulose) and
1 to 3 mg of magnesium stearate. 4. Schnellfreisetzende Tabletten-Formulierung gemäß den Ansprüchen 1 bis 3, die
10 mg des Wirkstoffes Fludara in einer Reinheit von > 99,19%, zusammen mit
74,75 mg Lactose Monohydrat,
0,75 mg kolloidalem Siliciumdioxid,
60,00 mg mikrokristalline Cellulose (Avicel),
3,00 mg Croscaramellose-Na (Natriumcarboxymethylcellulose) und
1,5-2,00 mg Magnesiumstearat umfaßt. 4. Fast-release tablet formulation according to claims 1 to 3, which
10 mg of the active substance Fludara in a purity of> 99.19%, together with
74.75 mg lactose monohydrate,
0.75 mg of colloidal silica,
60.00 mg of microcrystalline cellulose (Avicel),
3.00 mg croscaramellose Na (sodium carboxymethylcellulose) and
1.5-2.00 mg of magnesium stearate. 5. Schnellfreisetzende Tabletten-Formulierung gemäß den Ansprüchen 1 bis 4, die den Wirkstoff Fludara in einer Reinheit von > 99,37% umfaßt. 5. Fast-release tablet formulation according to claims 1 to 4, which the active ingredient Fludara in a purity of> 99.37%. 6. Schnellfreisetzende Tabletten-Formulierung gemäß den Ansprüchen 1 bis 5, die den Wirkstoff Fludara in einer Reinheit von > 99,57% umfaßt. 6. Fast-release tablet formulation according to claims 1 to 5, which the active ingredient Fludara in a purity of> 99.57%. 7. Schnellfreisetzende Tabletten-Formulierung gemäß den Ansprüchen 1 bis 6, die den Wirkstoff Fludara in einer Reinheit von > 99,80% umfaßt. 7. Fast-release tablet formulation according to claims 1 to 6, which the active ingredient Fludara in a purity of> 99.80%. 8. Schnellfreisetzende Tabletten-Formulierung gemäß den Ansprüchen 1 bis 7, die den Wirkstoff Fludara in einer Reinheit von > 99,85% umfaßt. 8. Fast-release tablet formulation according to claims 1 to 7, which the active ingredient Fludara in a purity of> 99.85%. 9. Schnellfreisetzende Tabletten-Formulierung gemäß den Ansprüchen 1 bis 8, dadurch gekennzeichnet, daß die Tablettenkerne von einem Überzug, der folgende Bestandteile umfaßt
1 bis 5 mg Hydroxypropylmethylcellulose,
0,1 bis 1 mg Talkum,
0,1 bis 5 mg Titandioxid,
0,01 bis 0,1 mg gelbes Eisenoxidpigment und
0,01 bis 0,1 mg rotes Eisenoxidpigment, umgeben ist 9. Fast-release tablet formulation according to claims 1 to 8, characterized in that the tablet cores of a coating comprising the following constituents
1 to 5 mg of hydroxypropylmethylcellulose,
0.1 to 1 mg talc,
0.1 to 5 mg of titanium dioxide,
0.01 to 0.1 mg of yellow iron oxide pigment and
0.01 to 0.1 mg of red iron oxide pigment is surrounded 10. Schnellfreisetzende Tabletten-Formulierung gemäß den Ansprüchen 1 bis 9, dadurch gekennzeichnet, daß die Tablettenkerne von einem Überzug, der folgende Bestandteile umfaßt
1 bis 3 mg Hydroxypropylmethylcellulose,
0,1 bis 0,8 mg Talkum,
0,1 bis 2 mg Titandioxid,
0,01 bis 0,05 mg gelbes Eisenoxidpigment und
0,01 bis 0,05 mg rotes Eisenoxidpigment, umgeben ist 10. Fast-release tablet formulation according to claims 1 to 9, characterized in that the tablet cores of a coating comprising the following constituents
1 to 3 mg of hydroxypropylmethylcellulose,
0.1 to 0.8 mg talc,
0.1 to 2 mg of titanium dioxide,
0.01 to 0.05 mg of yellow iron oxide pigment and
0.01 to 0.05 mg of red iron oxide pigment is surrounded 11. Schnellfreisetzende Tabletten-Formulierung gemäß den Ansprüchen 1 bis 10, dadurch gekennzeichnet, daß die Tablettenkerne von einem Überzug, der folgende Bestandteile umfaßt
2,250 mg Hydroxypropylmethylcellulose,
0,450 mg Talkum,
1,187 mg Titandioxid,
0,036 mg gelbes Eisenoxidpigment und
0,036 mg rotes Eisenoxidpigment, umgeben ist. 11. Fast-release tablet formulation according to claims 1 to 10, characterized in that the tablet cores of a coating comprising the following constituents
2,250 mg of hydroxypropylmethylcellulose,
0.450 mg talc,
1.187 mg of titanium dioxide,
0.036 mg yellow iron oxide pigment and
0.036 mg red iron oxide pigment is surrounded. 12. Verwendung der Tabletten-Formulierung gemäß den Ansprüchen 1 bis 11, zur Herstellung eines Medikaments zur Behandlung von Krebs. 12. Use of the tablet formulation according to claims 1 to 11, to Preparation of a drug for the treatment of cancer.
DE10164510A 2001-12-20 2001-12-20 Oral Fludara pure formulation with rapid release of the active ingredient Ceased DE10164510A1 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
DE10164510A DE10164510A1 (en) 2001-12-20 2001-12-20 Oral Fludara pure formulation with rapid release of the active ingredient
NZ533701A NZ533701A (en) 2001-12-20 2002-11-25 Ultrapure oral fludara formulation with a fast releasing active substance
CA002471396A CA2471396A1 (en) 2001-12-20 2002-11-25 Ultrapure oral fludara formulation with a fast releasing active substance
JP2003554177A JP2005519043A (en) 2001-12-20 2002-11-25 Oral fludara of high purity formulation with immediate release of active ingredient
CNB028279034A CN1306929C (en) 2001-12-20 2002-11-25 Ultrapure oral fludara formulation with a fast releasing active substance
RU2004122479/15A RU2318496C2 (en) 2001-12-20 2002-11-25 Ultra-pure fludara-containing oral composition with rapid releasing active substance
AU2002349043A AU2002349043B2 (en) 2001-12-20 2002-11-25 Ultrapure oral fludara formulation with a fast releasing active substance
PCT/EP2002/013252 WO2003053418A1 (en) 2001-12-20 2002-11-25 Ultrapure oral fludara formulation with a fast releasing active substance
MXPA04006005A MXPA04006005A (en) 2001-12-20 2002-11-25 Ultrapure oral fludara formulation with a fast releasing active substance.
EP02781328A EP1455760B1 (en) 2001-12-20 2002-11-25 Ultrapure oral fludara formulation with a fast releasing active substance
UA20040705884A UA78741C2 (en) 2001-12-20 2002-11-25 Fast releasing tablet formulation containing ultrapure fludara and its use
YUP-533/04A RS50398B (en) 2001-12-20 2002-11-25 Ultrapure oral fludara formulation with a fast releasing active substance
DE50204203T DE50204203D1 (en) 2001-12-20 2002-11-25 ORAL FLUDARA PURE FORMULATION WITH FAST RELEASE OF THE ACTIVE SUBSTANCE
PL370792A PL203451B1 (en) 2001-12-20 2002-11-25 Highly pure oral Fludara with rapid active ingredient release
ES02781328T ES2248624T3 (en) 2001-12-20 2002-11-25 PURISIMAL ORAL FORMULATION OF FLUDARA WITH FAST RELEASE OF ACTIVE SUBSTANCE.
BR0215265-7A BR0215265A (en) 2001-12-20 2002-11-25 High purity formulation oral fludara with quick release of active ingredient
DK02781328T DK1455760T3 (en) 2001-12-20 2002-11-25 Orla fludara - purest formulation with rapid release of the active substance
AT02781328T ATE303797T1 (en) 2001-12-20 2002-11-25 ORAL FLUDARA PURE FORMULATION WITH RAPID RELEASE OF THE ACTIVE INGREDIENTS
KR1020047009750A KR100884685B1 (en) 2001-12-20 2002-11-25 Ultra-Pure Fludala Oral Formulations Containing Rapid Release Active Substances
IL16255502A IL162555A0 (en) 2001-12-20 2002-11-25 Ultrapure oral fludara formulation with a fast releasing active substance
JO2002123A JO2363B1 (en) 2001-12-20 2002-12-10 Oral fludara pure formulation with immediate release of the active compound
UY27596A UY27596A1 (en) 2001-12-20 2002-12-19 ORAL FORMULATION OF PURISIMATE FLUDARA WITH RAPID RELEASE OF INGREDIENT
ARP020105054A AR037965A1 (en) 2001-12-20 2002-12-20 ORAL FORMULATION OF FLUDARA PURISIMO WITH QUICK RELEASE OF ACTIVE INGREDIENT
US10/324,141 US7148207B2 (en) 2001-12-20 2002-12-20 Oral fludara of high-purity formulation with quick release of active ingredient
TW091136814A TWI255187B (en) 2001-12-20 2002-12-20 Oral fludara of high-purity formulation with quick release of active ingredient
PE2003000017A PE20030639A1 (en) 2001-12-20 2003-01-06 ORAL FORMULATION OF FLUDARABIN WITH RAPID RELEASE OF THE ACTIVE INGREDIENT
SA03240091A SA03240091B1 (en) 2001-12-20 2003-04-27 A highly purified formulation of Fludara for oral administration with a rapid release of the active ingredient
IL162555A IL162555A (en) 2001-12-20 2004-06-16 Ultrapure oral fludara formulation with a fast releasing active substance
EC2004005185A ECSP045185A (en) 2001-12-20 2004-07-12 ORAL FORMULATION OF PURE FLUDARA WITH QUICK RELEASE OF ACTIVE INGREDIENT
HR20040648 HRP20040648B1 (en) 2001-12-20 2004-07-15 Ultrapure oral fludara formulation with a fast releasing active substance
ZA2004/05735A ZA200405735B (en) 2001-12-20 2004-07-19 Ultrapure oral fludara formulation with a fast releasing active substance
NO20043063A NO20043063L (en) 2001-12-20 2004-07-19 Hoyren, oral fludara formulation with rapid release of the active substance
HK05109796A HK1077741A1 (en) 2001-12-20 2005-11-03 Oral fludara of high-purity formulation with quickrelease of active ingredient
JP2005379628A JP2006137771A (en) 2001-12-20 2005-12-28 Oral fludara of high-purity formulation with quick release of active ingredient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10164510A DE10164510A1 (en) 2001-12-20 2001-12-20 Oral Fludara pure formulation with rapid release of the active ingredient

Publications (1)

Publication Number Publication Date
DE10164510A1 true DE10164510A1 (en) 2003-07-10

Family

ID=7711168

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10164510A Ceased DE10164510A1 (en) 2001-12-20 2001-12-20 Oral Fludara pure formulation with rapid release of the active ingredient
DE50204203T Expired - Lifetime DE50204203D1 (en) 2001-12-20 2002-11-25 ORAL FLUDARA PURE FORMULATION WITH FAST RELEASE OF THE ACTIVE SUBSTANCE

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE50204203T Expired - Lifetime DE50204203D1 (en) 2001-12-20 2002-11-25 ORAL FLUDARA PURE FORMULATION WITH FAST RELEASE OF THE ACTIVE SUBSTANCE

Country Status (30)

Country Link
US (1) US7148207B2 (en)
EP (1) EP1455760B1 (en)
JP (2) JP2005519043A (en)
KR (1) KR100884685B1 (en)
CN (1) CN1306929C (en)
AR (1) AR037965A1 (en)
AT (1) ATE303797T1 (en)
AU (1) AU2002349043B2 (en)
BR (1) BR0215265A (en)
CA (1) CA2471396A1 (en)
DE (2) DE10164510A1 (en)
DK (1) DK1455760T3 (en)
EC (1) ECSP045185A (en)
ES (1) ES2248624T3 (en)
HK (1) HK1077741A1 (en)
HR (1) HRP20040648B1 (en)
IL (2) IL162555A0 (en)
JO (1) JO2363B1 (en)
MX (1) MXPA04006005A (en)
NO (1) NO20043063L (en)
NZ (1) NZ533701A (en)
PE (1) PE20030639A1 (en)
RS (1) RS50398B (en)
RU (1) RU2318496C2 (en)
SA (1) SA03240091B1 (en)
TW (1) TWI255187B (en)
UA (1) UA78741C2 (en)
UY (1) UY27596A1 (en)
WO (1) WO2003053418A1 (en)
ZA (1) ZA200405735B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010133629A1 (en) * 2009-05-19 2010-11-25 Grindeks, A Joint Stock Company Stable pharmaceutical composition of fludarabine phosphate
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
CN101947208B (en) * 2010-10-09 2012-05-23 江苏奥赛康药业股份有限公司 Fludarabine phosphate composition for injection and preparation method thereof
CN102091046B (en) * 2011-02-12 2012-07-18 海南锦瑞制药股份有限公司 Fludarabine phosphate freeze-dried powder injection and preparation method thereof
US10669302B2 (en) * 2015-08-28 2020-06-02 Zhejianf Hisun Pharmaceutical Co., Ltd. Crystal form of fludarabine phosphate, preparation method therefor, and application thereof
CN111423458A (en) * 2020-04-29 2020-07-17 东南大学 Preparation method of fludarabine phosphate impurity H reference substance

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0819430A1 (en) * 1996-07-17 1998-01-21 Takeda Chemical Industries, Ltd. Inhibitor of tumor metastasis or recurrence
WO1999029710A2 (en) * 1997-12-11 1999-06-17 Schering Aktiengesellschaft Purification method for producing fludarabin phosphate

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903297A (en) * 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
US4210745A (en) * 1978-01-04 1980-07-01 The United States Of America As Represented By The Department Of Health, Education And Welfare Procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine
US4188378A (en) * 1978-01-04 1980-02-12 The United States Of America As Represented By The Department Of Health, Education And Welfare Anticancer and antiviral activity of 9-β-D-arabinofuranosyl-2-fluoroadenine
US4357324A (en) * 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
DE3323621A1 (en) * 1982-07-08 1984-03-01 Yamasa Shoyu K.K., Choshi, Chiba PHARMACEUTICAL PREPARATION WITH A REINFORCING ANTITUMOR EFFECT, A CHEMOTHERAPEUTIC COMPOSITION CONTAINING SUCH A PREPARATION AND USE OF THE PREPARATION TO SUPPORT ANTITUM TREATMENT AND TREATMENT IN MAN
US5110919A (en) * 1989-12-04 1992-05-05 Ash Stevens, Inc. Process for the preparation of 2-amino-9-(2,3,5-tri-o-benzyl-beta-d-arabinofuranosyl) adenine and novel intermediates
FR2701027B1 (en) * 1993-02-01 1997-07-18 Warner Lambert Co IMPROVED SYNTHESIS PROCESS OF 9- (BETA-D-ARABINOFURANOSYL) ADENINE 5'-PHOSPHATE.
DE19543052A1 (en) 1995-11-06 1997-05-07 Schering Ag Purifying fludarabine phosphate
DE69713948D1 (en) 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rapidly releasing pH-independent solid dosage forms containing cisapride
US6197785B1 (en) * 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
EA004311B1 (en) 1998-06-11 2004-02-26 Фармация Энд Апджон Компани A pharmaceutical tablet composition of durable action
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
WO2001014348A1 (en) 1999-08-20 2001-03-01 The Scripps Research Institute Formation of heterocycles
EP1175220B1 (en) 1999-12-08 2005-04-27 Pharmacia Corporation Nanoparticulate eplerenone compositions
US20020131988A1 (en) 1999-12-16 2002-09-19 Foster Todd P. Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
JP2003518478A (en) * 1999-12-16 2003-06-10 ファルマシア・アンド・アップジョン・カンパニー Implant composition containing melengestrol acetate and trenbolone acetate
US6399591B1 (en) * 2000-01-19 2002-06-04 Yung-Shin Pharmaceutical Ind. Co., Ltd. Chargeable pharmaceutical tablets

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0819430A1 (en) * 1996-07-17 1998-01-21 Takeda Chemical Industries, Ltd. Inhibitor of tumor metastasis or recurrence
WO1999029710A2 (en) * 1997-12-11 1999-06-17 Schering Aktiengesellschaft Purification method for producing fludarabin phosphate

Also Published As

Publication number Publication date
IL162555A (en) 2008-03-20
ES2248624T3 (en) 2006-03-16
RS50398B (en) 2009-12-31
AU2002349043A1 (en) 2003-07-09
SA03240091B1 (en) 2006-11-25
JP2006137771A (en) 2006-06-01
NO20043063L (en) 2004-07-19
RU2318496C2 (en) 2008-03-10
JO2363B1 (en) 2006-12-12
ZA200405735B (en) 2006-01-25
TW200305428A (en) 2003-11-01
HK1077741A1 (en) 2006-02-24
AU2002349043B2 (en) 2007-08-16
EP1455760A1 (en) 2004-09-15
RU2004122479A (en) 2005-05-20
BR0215265A (en) 2004-12-07
UA78741C2 (en) 2007-04-25
PE20030639A1 (en) 2003-08-28
IL162555A0 (en) 2005-11-20
TWI255187B (en) 2006-05-21
KR20040073501A (en) 2004-08-19
CA2471396A1 (en) 2003-07-03
DE50204203D1 (en) 2005-10-13
CN1306929C (en) 2007-03-28
EP1455760B1 (en) 2005-09-07
NZ533701A (en) 2006-03-31
MXPA04006005A (en) 2004-09-27
KR100884685B1 (en) 2009-02-18
CN1617713A (en) 2005-05-18
UY27596A1 (en) 2003-07-31
WO2003053418A1 (en) 2003-07-03
HRP20040648A2 (en) 2004-10-31
ECSP045185A (en) 2004-08-27
US7148207B2 (en) 2006-12-12
US20030176391A1 (en) 2003-09-18
AR037965A1 (en) 2004-12-22
RS53304A (en) 2006-10-27
HRP20040648B1 (en) 2012-11-30
JP2005519043A (en) 2005-06-30
ATE303797T1 (en) 2005-09-15
DK1455760T3 (en) 2006-01-02
PL370792A1 (en) 2005-05-30

Similar Documents

Publication Publication Date Title
DE69434479T2 (en) Tramadol-containing drug with controlled release of active ingredient
DE69000881T2 (en) MEDICINE PREPARATION CONTAINING 2-PROPYLVALERIC ACID WITH DELAYED RELEASE OF THE ACTIVE SUBSTANCE.
DE69225421T2 (en) Medicines containing sumatriptan
EP0439030B1 (en) Oral dosage forms containing pimobendan
EP0068191A2 (en) Oral forms of dipyridamole
EP0108898A1 (en) Oral galenical forms of mopidamol
DE10038108A1 (en) Pharmaceutical compositions
DE69814850T2 (en) PARACETAMOL CONTAINING SLICKABLE TABLET
EP1658852A1 (en) Oral pharmaceutical preparation containing ibandronat
DE60020501T3 (en) Trimetazidine-containing matrix tablet for prolonged release of active ingredient after oral administration
EP1128831A1 (en) Pharmaceutical moxifloxacin preparation
EP1509207B1 (en) Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
EP2072054A1 (en) Use of a ginkgo biloba leaf extract
DE60225686T2 (en) PARACETAMOL CONTAINING TABLET
DE102007027067A1 (en) Process for the preparation of a medicament containing vardenafil hydrochloride trihydrate
EP1455760B1 (en) Ultrapure oral fludara formulation with a fast releasing active substance
DE60002570T2 (en) SWALLOWABLE TABLETS HIGH IN N-ACETYLCYSTONE
DE69433012T2 (en) METHOD FOR PRODUCING ORAL DOSAGE FORMULATIONS CONTAINING DICLOFENAC
DE4315525B4 (en) Pharmaceutical composition
DE19710054A1 (en) Pharmaceutical preparation
DE19826517B4 (en) Process for the preparation of film-coated tablets with cyclophosphamide as active ingredient and cyclophosphamide film-coated tablet produced therefrom
EP0301373B1 (en) Products containing gallopamil and prazosine
EP1374859B1 (en) Solid pharmaceutical composition comprising tilidine hydrochloride
DE202006020223U1 (en) Pharmaceutical composition
EP1757274B1 (en) Effervescent composition against cold symptoms

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8131 Rejection